Literature DB >> 30143523

CSTF2-Induced Shortening of the RAC1 3'UTR Promotes the Pathogenesis of Urothelial Carcinoma of the Bladder.

Xin Chen1,2, Jia-Xing Zhang1,3, Jun-Hang Luo4, Song Wu5, Gang-Jun Yuan1,2, Ning-Fang Ma6, Yong Feng7, Mu-Yan Cai1, Ri-Xin Chen1, Jun Lu4, Li-Juan Jiang1,2, Jie-Wei Chen1, Xiao-Han Jin1, Hai-Liang Liu8, Wei Chen4, Xin-Yuan Guan1,9, Tie-Bang Kang1, Fang-Jian Zhou1,2, Dan Xie10.   

Abstract

Shortening of the 3' untranslated regions (3'UTR) of mRNA is an important mechanism for oncogene activation. However, 3'UTR alteration events, their pathologic functions, and underlying mechanisms in human urothelial carcinoma of the bladder (UCB) are not clear. Here, we combine RNA sequencing, bioinformatics, and clinical studies in two independent cohorts of patients with UCB to identify a novel RAC1 shorter 3'UTR isoform that is frequently expressed in UCB and is critical in the tumorigenesis and acquisition of a poor prognostic phenotype in patients. Short 3'UTR isoform of RAC1 substantially upregulated RAC1 expression by escaping from miRNA-targeted repression and played an essential oncogenic role in UCB pathogenesis. An important cleavage/polyadenylation factor, cleavage stimulation factor 2 (CSTF2), induced 3'UTR shortening of RAC1 in UCB by mediating slow transcriptional elongation at RAC1 Cotranscriptional recruitment of CSTF2 on the GUAAU motif at proximal polyadenylation site of RAC1 attenuated the recruitment of two transcription factors AFF1 and AFF4, causing the defects in elongation. CSTF2 regulated the tumorigenic functions of the shorter RAC1 isoform in UCB cells, enhancing cell proliferation, migration, and invasion. The combination of high expression of CSTF2 and high usage of RAC1 short-3'UTR isoform may be used as a powerful biomarker to predict poor prognosis in UCB. Our findings also suggest a CSTF2-regulated RAC1-3'UTR shortening program as an exploitable therapeutic strategy for patients with UCB.Significance: These findings demonstrate that the short isoform of RAC1 is critical in UCB tumorigenesis and may have implications for developing new therapeutic strategies to treat this disease. Cancer Res; 78(20); 5848-62. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30143523     DOI: 10.1158/0008-5472.CAN-18-0822

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Biological functions of RNA modification patterns that define tumor microenvironment and survival outcomes in testicular germ cell tumors.

Authors:  Weijun Tang; Jinke Qian; Shilei Qian
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Shortening of the KHDRBS1 3'UTR by alternative cleavage and polyadenylation alters miRNA-mediated regulation and promotes gastric cancer progression.

Authors:  Xin Yu; Weibiao Kang; Jiajia Zhang; Changyu Chen; Yi Liu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 3.  The Bidirectional Link Between RNA Cleavage and Polyadenylation and Genome Stability: Recent Insights From a Systematic Screen.

Authors:  Stefano Spada; Brian Luke; Sven Danckwardt
Journal:  Front Genet       Date:  2022-04-28       Impact factor: 4.772

Review 4.  Drivers of Gene Expression Dysregulation in Pancreatic Cancer.

Authors:  Swati Venkat; Abdulrahman A Alahmari; Michael E Feigin
Journal:  Trends Cancer       Date:  2021-02-19

Review 5.  Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders.

Authors:  Jamie Nourse; Stefano Spada; Sven Danckwardt
Journal:  Biomolecules       Date:  2020-06-17

Review 6.  RAC1 Takes the Lead in Solid Tumors.

Authors:  Pradip De; Jennifer Carlson Aske; Nandini Dey
Journal:  Cells       Date:  2019-04-26       Impact factor: 6.600

7.  RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.

Authors:  Yuenan Liu; Gong Cheng; Zhengshuai Song; Tianbo Xu; Hailong Ruan; Qi Cao; Keshan Wang; Lin Bao; Jingchong Liu; Lijie Zhou; Di Liu; Hongmei Yang; Ke Chen; Xiaoping Zhang
Journal:  Int J Oncol       Date:  2019-07-26       Impact factor: 5.650

8.  Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma.

Authors:  Swati Venkat; Arwen A Tisdale; Johann R Schwarz; Abdulrahman A Alahmari; H Carlo Maurer; Kenneth P Olive; Kevin H Eng; Michael E Feigin
Journal:  Genome Res       Date:  2020-02-06       Impact factor: 9.043

9.  Construction of Two Alternative Polyadenylation Signatures to Predict the Prognosis of Sarcoma Patients.

Authors:  Chuan Hu; Chuan Liu; Jianyi Li; Tengbo Yu; Jun Dong; Bo Chen; Yukun Du; Xiaojie Tang; Yongming Xi
Journal:  Front Cell Dev Biol       Date:  2021-06-14

10.  A novel alternative splicing-based prediction model for uteri corpus endometrial carcinoma.

Authors:  Li Gao; Zu-Cheng Xie; Jin-Shu Pang; Tian-Tian Li; Gang Chen
Journal:  Aging (Albany NY)       Date:  2019-01-14       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.